Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer save search
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
Published: 2023-12-07 (Crawled : 18:00) - biospace.com/
MRK | News | $103.88 -1.66% 0.02% 9.1M
|
Health Technology
|
| O: -0.61%
H: 0.01%
C: -1.61%
ylynk-008 keytruda lung merck cancer cell trial plus
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
Published: 2023-12-07 (Crawled : 14:30) - globenewswire.com
COGT | News | $8.75 1.74% 1.71% 1.1M
|
Health Technology
|
| O: 4.31%
H: 0.0%
C: 0.0%
breast symposium cancer preclinical potential
Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings
Published: 2023-12-07 (Crawled : 13:00) - prnewswire.com
EXAS | News | $64.96 -0.31% -0.31% 930K
|
Health Technology
|
| O: -0.64%
H: 0.25%
C: -0.47%
cancer awards sciences grants
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
Published: 2023-12-06 (Crawled : 23:00) - prnewswire.com
ANIX | $3.6 -8.4% -9.17% 1.1M
|
Health Technology
|
| O: 0.0%
H: 5.63%
C: -10.45%
vaccine breast positive cancer study
Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer
Published: 2023-12-06 (Crawled : 22:00) - biospace.com/
ILMN | News | $117.085 2.72% 2.64% 2.1M
|
Health Technology
|
| O: 1.56%
H: 0.0%
C: 0.0%
AZN | $63.5 -0.14% -0.14% 6.2M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
america lung conference test cancer
Metastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at Astounding 22% CAGR During the Study Period (2019-2032), assesses DelveInsight
Published: 2023-12-06 (Crawled : 22:00) - prnewswire.com
LLY 6 d | $588.27 -0.17% -0.1% 2.1M
|
Health Technology
|
| O: -0.06%
H: 0.1%
C: -0.0%
cancer study market
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
Published: 2023-12-06 (Crawled : 21:00) - prnewswire.com
ANIX | $3.6 -8.4% -9.17% 1.1M
|
Health Technology
|
| O: 0.0%
H: 5.63%
C: -10.45%
conference vaccine breast positive cancer ongoing study
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
Published: 2023-12-06 (Crawled : 17:00) - biospace.com/
CNSP | $2.05 -2.38% -2.44% 37K
|
Health Technology
|
| O: 0.47%
H: 0.0%
C: 0.0%
cure cancer treatment pharmaceuticals
BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS
Published: 2023-12-06 (Crawled : 14:30) - globenewswire.com
BCTX | $4.9 -3.16% -3.27% 67K
|
Professional, Scientific, and T...
|
| O: -0.76%
H: 0.0%
C: 0.0%
breast cancer sabcs topline advanced
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
JAGX | $0.2863 -10.53% -11.77% 4.2M
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
breast health life symposium cancer pharmaceuticals family study
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
NTRA S | $57.93 0.05% 0.05% 680K
|
Health Services
|
| O: 1.01%
H: 0.0%
C: 0.0%
breast cancer treatment sabcs
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
SGEN | $218.28 1.15% 1.14% 2M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
tukysa breast cancer
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
Published: 2023-12-06 (Crawled : 13:30) - globenewswire.com
CELC | $14.72 -1.8% -1.83% 150K
|
Commercial Services
|
| O: -1.02%
H: 0.0%
C: 0.0%
breast symposium cancer preclinical
Bionano Announces Presentations Featuring OGM Utility Across Blood Cancer Research at the American Society of Hematology (ASH) Annual Meeting
Published: 2023-12-06 (Crawled : 13:00) - globenewswire.com
BNGO | $1.505 -9.88% -10.96% 1.7M
|
Health Technology
|
| O: -5.0%
H: 0.0%
C: 0.0%
cancer blood research meeting
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
Published: 2023-12-06 (Crawled : 04:00) - globenewswire.com
PFE A | $28.63 -0.56% 0.0% 35M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
ARVN | $32.71 7.95% 7.37% 1.6M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
arv-471 conference breast symposium cancer program
Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen Inc., Arrien Pharmaceuticals LLC and more among the key companies in the market - Technavio
Published: 2023-12-05 (Crawled : 23:00) - prnewswire.com
NVS | News 1 d | $95.93 -1.15% 0.0% 1.2M
|
Health Technology
|
| O: 0.17%
H: 0.0%
C: 0.0%
GSK | $36.0 -0.47% 0.06% 2.2M
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: 0.0%
ABBV | News | $147.97 1.09% 0.05% 7.2M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
AZN | $63.5 -0.14% -0.14% 6.2M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
GOOGL | $136.94 5.32% 5.05% 55M
|
Technology Services
|
| O: 1.97%
H: 0.0%
C: 0.0%
GOOG | $138.415 5.32% 5.05% 38M
|
Technology Services
|
| O: 1.97%
H: 0.0%
C: 0.0%
tube companies abbvie cancer pharmaceuticals therapeutics market
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
Published: 2023-12-05 (Crawled : 18:00) - biospace.com/
IMGN M | $29.355 0.05% 0.05% 12M
|
Health Technology
| Email alert
Add to watchlist
elahere fda license review cancer application grants
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
Published: 2023-12-05 (Crawled : 14:00) - globenewswire.com
RNAZ 3 d | $0.2085 -9.35% -10.31% 1.6M
|
Professional, Scientific, and T...
|
| O: 1.91%
H: 0.0%
C: 0.0%
breast symposium cancer therapeutics
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials
Published: 2023-12-05 (Crawled : 13:30) - globenewswire.com
ABVC | News | $1.24 -8.15% -8.87% 430K
|
Wholesale Trade
|
| O: 5.07%
H: 1.38%
C: -0.69%
irwin cancer depression biopharma trials medical
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies
Published: 2023-12-05 (Crawled : 13:30) - prnewswire.com
HOTH | $1.29 4.03% 3.88% 140K
|
Health Technology
|
| O: 1.64%
H: 12.1%
C: 4.84%
cancer therapeutics
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
SLDB | News M | $5.89 72.22% 41.94% 12M
|
Health Technology
SVFD | News | $3.09 43.72% 30.42% 64M
|
FTEL | $2.04 43.66% 30.39% 110K
|
HPCO 4 | $0.4824 41.92% 29.54% 28M
|
ALGS | News | $0.6475 -5.06% 26.67% 2.1M
|
Health Technology
GTHX | $3.16 30.58% 23.42% 10M
|
Health Technology
KEQU | $22.5 27.62% 21.64% 24K
|
Producer Manufacturing
GSIT | $3.09 27.16% 21.36% 2.2M
|
Electronic Technology
SSKN P | $0.628 25.6% 20.38% 210K
|
Health Technology
GLUE | $3.66 22.82% 18.58% 510K
|
Professional, Scientific, and T...
Your saved searches
Save your searches and get alerts when important news are released.